A novel urine screening test that uses a protein, keratin 17 (K17), as a cancer biomarker reveals the test detects the presence of new or recurrent cases of bladder cancer. The methodology behind the test stems from research at Stony Brook University led by Kenneth Shroyer, MD, Ph.D. A study that details the finding of the test will be published in the American Journal of Clinical Pathology.